New study tracks Real-World use of teplizumab to delay type 1 diabetes

NCT ID NCT07457580

Recruiting now Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observes 60 people with stage 2 type 1 diabetes who received teplizumab as part of managed access programs. Researchers will review medical records to describe patient characteristics, monitoring practices, and how long it takes for diabetes to progress. The goal is to gain rapid insight into how teplizumab is being used in real-world clinical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: teplizumab
What this could lead to: If successful, this study could help doctors better understand which patients benefit most from teplizumab and how it affects diabetes progression in real-world settings.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be limited by small sample size and variability in real-world care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Investigational Site Number: 0560001
RECRUITING

Leuven, 3000, Belgium
Investigational Site Number: 2500001
RECRUITING

Bron, 69677, France
Investigational Site Number: 2500002
RECRUITING

Paris, 75015, France
Investigational Site Number: 2500003
RECRUITING

Paris, 75014, France
Investigational Site Number: 3800001
RECRUITING

Ancona, 60123, Italy
Investigational Site Number: 3800003
RECRUITING

Palermo, 90127, Italy
Investigational Site Number: 7240001
RECRUITING

Madrid, 28034, Spain
Investigational Site Number: 7240002
RECRUITING

Madrid, 28046, Spain
Investigational Site Number: 7240003
RECRUITING

Zaragoza, 50009, Spain
Investigational Site Number: 8260001
RECRUITING

Birmingham, B4 6NH, United Kingdom
Investigational Site Number: 8260002
RECRUITING

London, E1 1BB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.